,Overview of emerging treatment of non-alcoholic fatty liver disease: more than one drug needed?

• 作 者: Dong Yun Kim Jun Yong Park
• 机 构: Department of Pharmacology, Yonsei University Graduate School of Medicine, Seoul, South Korea“,”Depa
• 出 处: 肝胆外科与营养
• 发表日期: 2019年5期

Non-alcoholic fatty liver disease (NAFLD) comprisesisolated hepatic steatosis, non-alcoholic steatohepatitis(NASH), liver failure-associated complications of livercirrhosis, and liver cancer. These are forecasted to be theleading liver diseases in the future.